Cargando...
The Approval Process for Biosimilar Erythropoiesis-Stimulating Agents
A biosimilar drug or follow-on biologic drug is defined by the Public Health Service Act as a product that is “highly similar to the reference product notwithstanding minor differences in clinically active components and there are no clinically meaningful differences between the biologic product and...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society of Nephrology
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4152809/ https://ncbi.nlm.nih.gov/pubmed/24970875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.01770214 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|